Hyperglucagonaemia analysed by glucagon sandwich ELISA: Nonspecific interference or truly elevated levels?

Diabetologia

Volumn 57, Issue 9, 2014, Pages 1919-1926

  Wewer Albrechtsen, Nicolai J ^a   Hartmann, Bolette ^a   Veedfald, Simon ^a   Windeløv, Johanne A ^a   Plamboeck, Astrid ^a   Bojsen Møller, Kirstine N ^b   Idorn, Thomas ^b   Feldt Rasmussen, Bo ^b   Knop, Filip K ^b   Vilsbøll, Tina ^b   Madsbad, Sten ^b   Deacon, Carolyn F ^a   Holst, Jens J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Diabetes; End stage renal disease; Gastric bypass; Glucagon; Hyperglucagonaemia

Indexed keywords

GLICENTIN; GLUCAGON; OXYNTOMODULIN;

ARTICLE; CONTROLLED STUDY; CROSS REACTION; END STAGE RENAL DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCAGON BLOOD LEVEL; HUMAN; HYPERGLUCAGONEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PYLOROPLASTY; ROUX Y ANASTOMOSIS; VAGOTOMY; CARBOXY TERMINAL SEQUENCE; ELISA KIT; IMMUNOREACTIVITY; KIDNEY DISEASE; ORAL GLUCOSE TOLERANCE TEST; POSTOPERATIVE PERIOD; SENSITIVITY AND SPECIFICITY; BLOOD; CHRONIC KIDNEY FAILURE; PROCEDURES; STOMACH BYPASS;

ENZYME-LINKED IMMUNOSORBENT ASSAY; GASTRIC BYPASS; GLUCAGON; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 84905594726     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3283-z     Document Type: Article

References (24)

1. Bell GI, Santerre RF, Mullenbach GT (1983) Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302:716-718
2. Holst JJ, Christensen M, Lund A, et al. (2011) Regulation of glucagon secretion by incretins. Diabetes Obes Metab 13(Suppl 1):89-94
3. Ohneda A, Ohneda M (1988) Effect of glicentin-related peptides upon the secretion of insulin and glucagon in the canine pancreas. Tohoku J Exp Med 155:197-204
4. Brand CL, Jorgensen PN, Svendsen I, Holst JJ (1996) Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 45:1076-1083
5. Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM (1970) Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 49:837-848
6. Toft-Nielsen MB, Madsbad S, Holst JJ (2001) Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 86:3853-3860
7. Bojsen-Møller KN, Dirksen C, Jørgensen NB, et al. (2014) Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes 63:1725-1737
8. Plamboeck A, Veedfald S, Deacon CF, et al. (2013) The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am J Physiol Gastrointest Liver Physiol 304:G1117-G1127
9. Idorn T, Knop FK, Jorgensen M, Holst JJ, Hornum M, Feldt-Rasmussen B (2013) Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease. Kidney Int 83:915-923
10. Holst JJ (1982) Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. Biochem J 207:381-388
11. Baldissera FG, Holst JJ (1986) Glicentin 1-61 probably represents a major fraction of glucagon-related peptides in plasma of anaesthetized uraemic pigs. Diabetologia 29:462-467
12. Trebbien R, Klarskov L, Olesen M, Holst JJ, Carr RD, Deacon CF (2004) Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs. Am J Physiol Endocrinol Metab 287:E431-E438
13. Bak MJ, Albrechtsen NW, Pedersen J, et al. (2014) Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. Eur J Endocrinol 170:529-538
14. Holst JJ (1980) Evidence that glicentin contains the entire sequence of glucagon. Biochem J 187:337-343
15. Bak MJ, Albrechtsen NW, Hartmann B, et al. (2014) Effect of aprotinin (Trasylol™) on degradation of exogenous and endogenous glucagon in human, mouse and rat plasma. J Endocrinol Diabetes 1:5
16. Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S (2011) Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 34:S251-S257
17. Holst JJ, Pedersen JH, Baldissera F, Stadil F (1983) Circulating glucagon after total pancreatectomy in man. Diabetologia 25:396-399
18. Holst JJ (1983) Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin - current status. Gastroenterology 84:1602-1613
19. Meier JJ, Ueberberg S, Korbas S, Schneider S (2011) Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell mass. Am J Physiol Endocrinol Metab 300:E717-E723
20. Gäreskog MCA, Schwanbeck M, Karamihos E, et al. (2013) Development and validation of a high-sensitivity ELISA forspecific measurement of glucagon in rat and mouse samples. IDF 2013 Abstract PD-0657
21. Deacon CF, Kelstrup M, Trebbien R, Klarskov L, Olesen M, Holst JJ (2003) Differential regional metabolism of glucagon in anesthetized pigs. Am J Physiol Endocrinol Metab 285:E552-E560
22. Plamboeck A, Veedfald S, Deacon CF, et al. (2013) Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty. Eur J Endocrinol 169:187-201
23. Meier JJ, Gallwitz B, Siepmann N, et al. (2003) Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46:798-801
24. Shah M, Law JH, Micheletto F, et al. (2014) Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes 63:483-493